DiaSorin S.p.A. (BIT:DIA)

Market Cap	3.15B
Revenue (ttm)	1.21B
Net Income (ttm)	184.11M
Shares Out	53.94M
EPS (ttm)	3.41
PE Ratio	17.10
Forward PE	13.51
Dividend	1.20 (2.06%)
Ex-Dividend Date	May 19, 2025

Volume	224,540
Average Volume	339,608
Open	58.66
Previous Close	58.36
Day's Range	58.18 - 59.80
52-Week Range	58.18 - 108.00
Beta	0.53
RSI	20.54
Earnings Date	Nov 5, 2025

About DiaSorin

DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/sepsis, bone metabolism, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urin...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1968
• Employees: 3,308
• Stock Exchange: Borsa Italiana
• Ticker Symbol: DIA

Financial Performance

In 2024, DiaSorin's revenue was 1.19 billion, an increase of 3.24% compared to the previous year's 1.15 billion. Earnings were 188.11 million, an increase of 17.68%.